Ayretrade Inc (SUMM) 0.0610 $SUMM First Patient Enrolled

New Post Public Reply Private Reply Replies (0) Message Board

Jun 19, 2016 at 6:05 AM

Ayretrade Inc (SUMM) 0.0610 $SUMM

First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD. Ezutromid dosing is expected to follow a screening period of up to 28 days.
SMMT: 8.09 (+0.08)

Summit Therapeutics to Host Utrophin R&D Day 15 June 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit's management on 15 June 2016 in New York City.
SMMT: 8.09 (+0.08)

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the first quarter ended 30 April 2016.
SMMT: 8.09 (+0.08)

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 8.09 (+0.08)

Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.
SMMT: 8.09 (+0.08)

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016.
SMMT: 8.09 (+0.08)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
SMMT: 8.09 (+0.08)

Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection ('CDI'

, announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office.
SMMT: 8.09 (+0.08)

Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 8.09 (+0.08)

Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces the presentation today of major findings from the Phase 2 CoDIFy trial highlighting the potential of ridinilazole in the treatment of CDI at the 26 European Congress of Clinical Microbiology and Infectious Diseases ('ECCMID'

. These findings include a markedly reduced recurrence rate and a statistically superior rate of sustained clinical response ('SCR'

in patients with CDI receiving ridinilazole compared with those receiving the standard of care, vancomycin. Ridinilazole is a novel class antibiotic with the potential for broad use across the CDI disease spectrum.
SMMT: 8.09 (+0.08)

Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company's 15 Annual Healthcare Conference, 13 April 2016 at 11:20am EDT in New York City.
SMMT: 8.09 (+0.08)

Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, announces positive interim data from a Phase 1 clinical trial evaluating a new oral formulation of its lead utrophin modulator, SMT C1100, for DMD. In this dose escalating clinical trial's initial dosing period, all patients achieved plasma drug levels within the range believed to be necessary for a potential therapeutic benefit. The initial dose tested of the new formulation was one tenth of that required with the current formulation of SMT C1100 to achieve similar drug concentration levels in the recent Phase 1b modified diet clinical trial of SMT C1100.
SMMT: 8.09 (+0.08)

Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
GlobeNewswire - Tue Mar 29, 8:25AM CDT
-- Data to be Presented at 26 ECCMID Conference, 11 April 2016
SMMT: 8.09 (+0.08)

Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
GlobeNewswire - Tue Mar 15, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, announces the online publication on the development of imaging techniques designed to quantify utrophin protein and muscle fibre regeneration in muscle biopsies from patients with DMD and Becker muscular dystrophy ('BMD'

.
SMMT: 8.09 (+0.08)

Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
GlobeNewswire - Mon Mar 07, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces additional positive data from the CoDIFy Phase 2 clinical trial that show the narrow spectrum antibiotic ridinilazole preserves the gut microbiome in CDI patients while the standard of care, vancomycin, inflicts substantial and long-lasting damage on the gut microbiome.
SMMT: 8.09 (+0.08)

Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 8.09 (+0.08)

Summit Financial Group Reports Fourth Quarter and Full Year 2015 Results
GlobeNewswire - Mon Jan 25, 5:00AM CST
Summit Financial Group, Inc. ("Company" or "Summit"

(NASDAQ:SMMF) today reported fourth quarter 2015 net income applicable to common shares of $4.15 million, or $0.39 per diluted share, compared to $3.01 million, or $0.32 per diluted share, for the fourth quarter of 2014, representing an increase of 37.8 percent, or 21.9 percent per diluted share. Q4 2015 earnings compared to Q4 2014 were positively impacted by a $782,000 increase in net interest income and a $314,000 gain on sale of foreclosed properties, but were negatively impacted by a $336,000 increase in write-downs of foreclosed properties and a $250,000 provision for loan losses compared to zero for Q4 2014.
SMMF: 15.88 (-1.09)

Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles.
SMMT: 8.09 (+0.08)

Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the European Patent Office ('EPO'

has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile.
SMMT: 8.09 (+0.08)

Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
GlobeNewswire - Thu Dec 17, 6:00AM CST
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the third quarter ended 31 October 2015.
SMMT: 8.09 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunrate's Bold Move: New Payment Bond with Netstorming

Sunrate Joins Forces with Netstorming When two industry powerhouses shake hands, it's wise to sit up and listen. Sunrate, the global whiz in payment solutions, has linked arms with Netstorming, a tech-savvy pioneer in the travel sector. This ironclad partnership was announced at World Travel Market London 2026. Owners of travel businesses should take note: things are...

Tellus Offers Seamless Security with Passkey Sign-In

Tellus Brings a New Era of Convenience Even the most innovative, forward-thinking companies occasionally have to change step to keep up with the relentless march of technology. That's what Tellus App, Inc., a proptech company from Silicon Valley, is doing with its latest announcement to offer passkey sign-ins for its savings app across iOS, Android, and the web. In...

Mill Creek's Bold Move into Denver's Cherry Creek

Taking a Stroll Down Cherry Creek The move by Mill Creek Residential into Cherry Creek North is a bold one, but they aren't exactly newcomers to this high-end neighborhood. They're planting their flag with the Modera Second Avenue, targeting Denver's upscale renters. With a Walk Score of 89, the location is a sweet spot for deep-pocketed folks who want the boutiques and...

BAIC FOTON Expands With New Trucks in Africa

By Lucas Young Updated Nov 3, 2026 Category News Views 123

Innovation in African Mobility Amidst the sparse horizons of Port Elizabeth, South Africa, BAIC FOTON is shifting gears in a big way. They've rolled out a duo of heavy-duty trucks—the GALAXUS R5 and C5—and topped it off with the TUNLAND V PHEV plug-in hybrid pickup. On October 29, the Africa Regional Partner Conference buzzed with talk of 'Driving to Great,' signaling...

LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...

Fluence Energy Faces Stock Woes Amid Legal Challenges

A Wild Ride for Fluence Energy Shareholders Damn, if you blinked, you might've missed the plummet of Fluence Energy, Inc. (NASDAQ:FLNC). This kind of nosedive, a brutal 34.63% drop, is the stuff investors fear most. It's like finding a flat tire on the road to profits. But here we are, dissecting the mess that unfolded between November 2025 and September 2026. The meat on...

Levvy AI: Transforming Hidden Hours into Advisory Gold

Unlocking Hidden Potential: Levvy AI on the Scene Picture this: you're running an accounting shop and drowning in an ocean of endless tasks, manual entries, and those cursed follow-ups. That's probably the daily grind, right? Well, it looks like Levvy has decided to break those shackles. This company, based over there in Brooklyn, is rolling out these fancy Levvy AI...

Speakeasy Dispensary Brings Medical Cannabis to Maysville

New Chapter for Maysville: Speakeasy Opens Doors Normally, you'd think of medical cannabis expansions as dry numbers and policies, but with Speakeasy Dispensary making its mark in Maysville, it's not just about business; it's a service to the community. Nestled into 317 W 2nd St, this is more than a simple retail spot. It's about bringing medical options straight to the...

BAC Faces Class Action as Compliance Issues Loom

The air around Bank of America (NYSE: BAC) has turned a shade darker, and if you've been following the script, this was only a matter of time. With Capitol Hill heavies like Senator Elizabeth Warren banging the drum, the squabble over compliance isn't just noise—it's a full-blown siren wailing in the middle of the trading floor. Enforcement and Reaction: A Boiling Pot...

Connecting NIH Data: Transforming Scientific Discoveries

Rethinking How Research Data Drives Discovery When researchers generate truckloads of data, finding patterns that lead to breakthroughs often becomes a game of hide and seek. It's like having a jumbo puzzle with pieces scattered all over the place. Enter the NIH Common Fund Data Ecosystem—a game changer attempting to glue together these pieces across the research...